8-K Announcements
6Material company update
Apr 21, 2026·SEC
Material company update
Mar 10, 2026·SEC
Material company update
Jan 7, 2026·SEC
Rapport Therapeutics, Inc. Common Stock(RAPP)Earnings, Financials & Key Ratios
RAPP•NASDAQ
$37.06
$1.35B mkt cap·Price updated May 6, 2026
AboutRapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. Its lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. The company also develops RAP-199, a TARPy8 targeted molecule with differentiated chemical and pharmacokinetic properties; and nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and a9a10 nAChR for the treatment of hearing disorders. The company was formerly known as Precision Neuroscience NewCo, Inc. and changed its name to Rapport Therapeutics, Inc. in October 2022. Rapport Therapeutics, Inc. was incorporated in 2022 and is based in Boston, Massachusetts.Show more
- Revenue$0
- EBITDA-$124M-50.9%
- Net Income-$111M-42.4%
- EPS (Diluted)-2.86-652.6%
- ROE-28.22%+49.6%
- ROIC-27.05%+66.0%
- Debt/Equity0.02+390.3%
RAPP Key Insights
Rapport Therapeutics, Inc. Common Stock (RAPP) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Momentum leader: RS Rating 87 (top 13%)
✗Weaknesses
- ✗Weak Piotroski F-Score: 2/9
- ✗Shares diluted 100.0% in last year
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
RAPP Price & Volume
Rapport Therapeutics, Inc. Common Stock (RAPP) stock price & volume — 10-year historical chart
Loading chart...
RAPP Growth Metrics
Rapport Therapeutics, Inc. Common Stock (RAPP) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-42.37%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-472.71%
Return on Capital
10 Years-35.9%
5 Years-35.9%
3 Years-36.32%
Last Year-31.29%
RAPP Recent Earnings
Rapport Therapeutics, Inc. Common Stock (RAPP) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (71%)
Q2 2026Latest
Mar 10, 2026EPS
$0.72
Est $0.65
-10.8%
Revenue
—
Q4 2025
Nov 6, 2025EPS
$0.71
Est $0.77
+7.8%
Revenue
—
Q3 2025
Aug 7, 2025EPS
$0.75
Est $0.87
+13.8%
Revenue
—
Q2 2025
May 8, 2025EPS
$0.68
Est $0.77
+11.7%
Revenue
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 10, 2026 | $0.72vs $0.65-10.8% | — |
| Q4 2025 | Nov 6, 2025 | $0.71vs $0.77+7.8% | — |
| Q3 2025 | Aug 7, 2025 | $0.75vs $0.87+13.8% | — |
| Q2 2025 | May 8, 2025 | $0.68vs $0.77+11.7% | — |
Based on last 12 quarters of dataView full earnings history →
RAPP Peer Comparison
Rapport Therapeutics, Inc. Common Stock (RAPP) competitors in Neuroscience and Psychiatry Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 PTCT | 5.52B | 66.61 | 8.56 | 114.51% | 39.44% | |||
 ACAD | 3.68B | 21.48 | 9.38 | 11.87% | 36.49% | 41.9% | 0.04 | |
 PRAX | 7.61B | 337.95 | -25.07 | -100% | -58.74% | 0.00 | ||
 INVA | 1.91B | 22.52 | 6.82 | 18.52% | 118.91% | 46.47% | 0.23 | |
 NKTR | 1.67B | 85.09 | -8.75 | -43.89% | -192.87% | -356.81% | 0.95 | |
 LGND | 4.57B | 232.55 | -1057.05 | 27.28% | 19.34% | 5.11% | 0.01 | |
 ARVN | 656.24M | 10.26 | -8.02 | -0.3% | -30.77% | -14.25% | 0.02 | |
 AXSM | 11.46B | 222.63 | -60.50 | 65.55% | -26.59% | -260.01% | 2.73 |
Compare RAPP vs Peers
Rapport Therapeutics, Inc. Common Stock (RAPP) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
RAPP Income Statement
Rapport Therapeutics, Inc. Common Stock (RAPP) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - |
| Cost of Goods Sold | 15K | 112K | 839K | 1.02M |
| COGS % of Revenue | - | - | - | - |
| Gross Profit | -15K▲ 0% | -112K▼ 646.7% | -839K▼ 649.1% | -1.02M▼ 21.2% |
| Gross Margin % | - | - | - | - |
| Gross Profit Growth % | - | -646.67% | -649.11% | -21.22% |
| Operating Expenses | 10.35M | 36.07M | 82.22M | 125.1M |
| OpEx % of Revenue | - | - | - | - |
| Selling, General & Admin | 1.37M | 8.07M | 22.12M | 30.31M |
| SG&A % of Revenue | - | - | - | - |
| Research & Development | 9.12M | 28M | 60.94M | 94.79M |
| R&D % of Revenue | - | - | - | - |
| Other Operating Expenses | -128.82K | 0 | -839K | 0 |
| Operating Income | -10.37M▲ 0% | -36.18M▼ 249.0% | -83.06M▼ 129.6% | -125.1M▼ 50.6% |
| Operating Margin % | - | - | - | - |
| Operating Income Growth % | - | -248.98% | -129.57% | -50.62% |
| EBITDA | -10.35M | -36.07M | -82.22M | -124.08M |
| EBITDA Margin % | - | - | - | - |
| EBITDA Growth % | - | -248.41% | -127.95% | -50.92% |
| D&A (Non-Cash Add-back) | 15K | 112K | 839K | 1.02M |
| EBIT | -10.37M | -34.78M | -78.31M | -125.1M |
| Net Interest Income | -285K | 2.53M | 12.14M | 13.62M |
| Interest Income | 0 | 2.53M | 12.14M | 13.62M |
| Interest Expense | 285K | 0 | 0 | 0 |
| Other Income/Expense | -285K | 1.4M | 4.75M | 13.62M |
| Pretax Income | -10.65M▲ 0% | -34.78M▼ 226.5% | -78.31M▼ 125.2% | -111.48M▼ 42.4% |
| Pretax Margin % | - | - | - | - |
| Income Tax | 0 | 10K | 0 | 0 |
| Effective Tax Rate % | 0% | -0.03% | 0% | 0% |
| Net Income | -10.65M▲ 0% | -34.79M▼ 226.6% | -78.31M▼ 125.1% | -111.48M▼ 42.4% |
| Net Margin % | - | - | - | - |
| Net Income Growth % | - | -226.57% | -125.11% | -42.37% |
| Net Income (Continuing) | -10.65M | -34.79M | -78.31M | -111.48M |
| Discontinued Operations | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.05▲ 0% | -0.19▼ 258.5% | -0.38▼ 100.0% | -2.86▼ 652.6% |
| EPS Growth % | - | -258.49% | -100% | -652.63% |
| EPS (Basic) | -0.05 | -0.19 | -0.38 | -2.86 |
| Diluted Shares Outstanding | 20.12M | 18.08M | 20.74M | 46.98M |
| Basic Shares Outstanding | 20.12M | 18.08M | 20.74M | 46.98M |
| Dividend Payout Ratio | - | - | - | - |
RAPP Balance Sheet
Rapport Therapeutics, Inc. Common Stock (RAPP) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|
| Total Current Assets | 31.27M | 150.87M | 309.8M | 498.56M |
| Cash & Short-Term Investments | 31.16M | 147.48M | 305.28M | 490.54M |
| Cash Only | 31.16M | 70.17M | 56.8M | 52.65M |
| Short-Term Investments | 0 | 77.31M | 248.47M | 437.89M |
| Accounts Receivable | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - |
| Other Current Assets | 0 | 3.39M | 4.52M | 8.02M |
| Total Non-Current Assets | 335K | 4.55M | 5.13M | 13.87M |
| Property, Plant & Equipment | 335K | 4M | 4.97M | 12.88M |
| Fixed Asset Turnover | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 551K | 160K | 985K |
| Total Assets | 31.6M▲ 0% | 155.42M▲ 391.8% | 314.93M▲ 102.6% | 512.43M▲ 62.7% |
| Asset Turnover | - | - | - | - |
| Asset Growth % | - | 391.8% | 102.63% | 62.71% |
| Total Current Liabilities | 1.66M | 8.8M | 8.77M | 19.05M |
| Accounts Payable | 1.45M | 2.5M | 1.95M | 4.19M |
| Days Payables Outstanding | 35.28K | 8.15K | 850.07 | 1.5K |
| Short-Term Debt | 0 | 0 | 0 | 2.75M |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 2.41M | 3.71M | 12.1M |
| Current Ratio | 18.80x | 17.14x | 35.34x | 26.17x |
| Quick Ratio | 18.80x | 17.14x | 35.34x | 26.17x |
| Cash Conversion Cycle | - | - | - | - |
| Total Non-Current Liabilities | 10.44M | 172.25M | 739K | 8.73M |
| Long-Term Debt | 10.44M | 0 | 0 | 8.73M |
| Capital Lease Obligations | 0 | 1.48M | 739K | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 170.78M | 0 | 0 |
| Total Liabilities | 12.1M | 181.06M | 9.51M | 27.78M |
| Total Debt | 10.44M | 2.15M | 1.48M | 11.48M |
| Net Debt | -20.72M | -68.02M | -55.33M | -41.16M |
| Debt / Equity | 0.53x | - | 0.00x | 0.02x |
| Debt / EBITDA | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - |
| Interest Coverage | -36.38x | - | - | - |
| Total Equity | 19.5M▲ 0% | -25.63M▼ 231.4% | 305.43M▲ 1291.5% | 484.65M▲ 58.7% |
| Equity Growth % | - | -231.42% | 1291.49% | 58.68% |
| Book Value per Share | 0.97 | -1.42 | 14.73 | 10.32 |
| Total Shareholders' Equity | 19.5M | -25.63M | 305.43M | 484.65M |
| Common Stock | 31K | 4K | 37K | 48K |
| Retained Earnings | -10.65M | -45.44M | -123.75M | -235.23M |
| Treasury Stock | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 4K | -522K | 546K |
| Minority Interest | 0 | 0 | 0 | 0 |
RAPP Cash Flow Statement
Rapport Therapeutics, Inc. Common Stock (RAPP) cash flow — operating, investing & free cash flow history
| Line item | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|
| Cash from Operations | -3.24M | -27.18M | -64.83M | -87.47M |
| Operating CF Margin % | - | - | - | - |
| Operating CF Growth % | - | -738.4% | -138.5% | -34.93% |
| Net Income | -10.65M | -34.79M | -78.31M | -111.48M |
| Depreciation & Amortization | 16.36K | 112K | 839K | 0 |
| Stock-Based Compensation | 609.82K | 3.52M | 10.23M | 0 |
| Deferred Taxes | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 5.3M | 1.32M | 4.82M | 24.01M |
| Working Capital Changes | 1.49M | 2.65M | -2.42M | 0 |
| Change in Receivables | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 |
| Change in Payables | 0 | 856K | -346K | 0 |
| Cash from Investing | -5.28M | -78.86M | -170.14M | -187.47M |
| Capital Expenditures | -284K | -1.64M | -2.4M | 0 |
| CapEx % of Revenue | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - |
| Other Investing | -5M | 0 | 3.21M | -187.47M |
| Cash from Financing | 39.69M | 145.14M | 221.63M | 270.79M |
| Debt Issued (Net) | 7.9M | 0 | 0 | 0 |
| Equity Issued (Net) | 31.79M | 145.27M | 221.62M | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | -4K | 0 | 0 |
| Other Financing | 0 | -134K | 7K | 270.79M |
| Net Change in Cash | 31.16M▲ 0% | 39.09M▲ 25.5% | -13.34M▼ 134.1% | -4.16M▲ 68.8% |
| Free Cash Flow | -3.53M▲ 0% | -28.82M▼ 717.3% | -67.23M▼ 133.3% | -88.09M▼ 31.0% |
| FCF Margin % | - | - | - | - |
| FCF Growth % | - | -717.27% | -133.31% | -31.02% |
| FCF per Share | -0.18 | -1.59 | -3.24 | -1.88 |
| FCF Conversion (FCF/Net Income) | 0.30x | 0.78x | 0.83x | 0.78x |
| Interest Paid | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 |
RAPP Key Ratios
Rapport Therapeutics, Inc. Common Stock (RAPP) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Return on Equity (ROE) | -54.61% | - | -55.97% | -28.22% |
| Return on Invested Capital (ROIC) | - | - | -79.64% | -27.05% |
| Debt / Equity | 0.53x | - | 0.00x | 0.02x |
| Interest Coverage | -36.38x | - | - | - |
| FCF Conversion | 0.30x | 0.78x | 0.83x | 0.78x |
RAPP SEC Filings & Documents
Rapport Therapeutics, Inc. Common Stock (RAPP) SEC filings — annual & quarterly reports (10-K, 10-Q)
RAPP Frequently Asked Questions
Rapport Therapeutics, Inc. Common Stock (RAPP) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Rapport Therapeutics, Inc. Common Stock (RAPP) grew revenue by 0.0% over the past year. Growth has been modest.
Rapport Therapeutics, Inc. Common Stock (RAPP) reported a net loss of $111.5M for fiscal year 2025.
Dividend & Returns
Rapport Therapeutics, Inc. Common Stock (RAPP) has a return on equity (ROE) of -28.2%. Negative ROE indicates the company is unprofitable.
Rapport Therapeutics, Inc. Common Stock (RAPP) had negative free cash flow of $87.9M in fiscal year 2025, likely due to heavy capital investments.
Explore More RAPP
Rapport Therapeutics, Inc. Common Stock (RAPP) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates